Parkinson’s disease (PD) affects more than 6 million people worldwide, yet the gold-standard treatment was approved over 30 years ago.1,2 With a robust early-stage pipeline, the absence of new, transformative treatments is not the result of a lack of interest but of the high failure rate following Phase II clinical trials.3 So, how can developers increase their probability of success?
To propel the field toward its next breakthrough, success hinges on trial designs that reflect the complexities of PD and accommodate the varying needs of patients.
In this webinar, the featured speakers will explore essential strategies for executing successful PD clinical trials. Topics will include collaborating with patient advocacy groups, using innovative study designs, selecting the appropriate symptom scales and protecting study endpoints. At the heart of it all: putting the patient first.
Register for this webinar to learn how to improve success in PD clinical trials through patient-centric and data-driven design.
Reference:
- The Michael J. Fox Foundation for Parkinson’s Research. (2025). Parkinson’s 101. https://www.michaeljfox.org/parkinsons-101
- BioSpace. (2024, December 10). 7 most promising drugs in Parkinson’s disease treatment pipeline. https://www.biospace.com/press-releases/7-most-promising-drugs-in-parkinsons-disease-treatment-pipeline
- McFarthing, K., Buff, S., Rafaloff, G., Pitzer, K., Fiske, B., Navangul, A., Beissert, K., Pilcicka, A., Fuest, R., Wyse, R. K., & Stott, S. R. W. (2024). Parkinson’s disease drug therapies in the clinical trial pipeline: 2024 update. Journal of Parkinson’s Disease, 14(5), 899–912. https://doi.org/10.3233/JPD-240272
Speakers
Antonio Hernandez, PsyD, Vice President, Program Strategy, Neuroscience, Premier Research
Dr. Antonio Hernandez is a Neuropsychologist by training, having completed his postdoctoral work at the Mount Sinai Medical Center (Wein Center for Alzheimer’s Disease & Memory Disorders) and North Broward Medical Center in Pompano Beach, Florida. He is a subject matter expert in endpoint selection, biomarker insights, protocol writing, clinical trial design, eCOA, rater training, data surveillance, investigator relations and enrollment diversity.
Most recently, as AVP of Clinical Research at Cassava Sciences, he co-designed and led the open-label study and Phase II/III multinational program in Alzheimer’s disease. Prior to this, he served as a Sr. Clinical Scientist at Bracket Global, providing CNS therapeutic expertise on the development of multiple CNS and neurology assets.
Message Presenter
Melissa Snyder, PhD, Executive Director, Program Strategy, Neuroscience, Premier Research
As Executive Director of Program Strategy, Dr. Melissa Snyder is responsible for strategic planning, coordination, knowledge and subject matter expertise for projects and consultative services. She contributes to designing effective and efficient clinical trials/programs, bringing specific regulatory, medical/scientific and operational knowledge in neuroscience. Previously, Melissa worked as Director of Clinical Research for a small biotechnology company. There, working closely with the Chief Medical Officer, Clinical Operations and Regulatory teams, Melissa supported Phase I-III clinical studies, including clinical trial design, protocol writing, statistical analysis plan development and trial oversight. In her previous position at a clinical research site, she established visibility within the community and formed strategic partnerships, increasing the patient database and clinical trial offerings.
Melissa spent years in basic science research exploring the pathophysiological mechanisms of epilepsy, schizophrenia and Alzheimer’s disease. Her therapeutic areas of expertise for clinical trials include Alzheimer’s disease, major depressive disorder and Tuberous Sclerosis Complex. Her clinical trial work spanned the United States, Canada, Australia and the Republic of Korea. Melissa earned her PhD in Neuroscience from Northwestern University in Evanston, IL and a BSc in Neuroscience from Allegheny College in Meadville, PA.
Message PresenterWho Should Attend?
This webinar will benefit Managers and above at biotech and specialty pharma companies with job functions including, but not limited to:
- Drug Development
- Clinical Operations
- Medical Affairs
- Regulatory Affairs
- Project Management
What You Will Learn
Attendees will gain insights about:
- PD therapeutic market landscape and pipeline
- Effectively collaborating with patient advocacy groups
- Employing unique study design strategies
- Protecting study endpoints to ensure clean, conclusive results
Xtalks Partner
Premier Research
Premier Research, a global clinical research, product development, and consulting company, is dedicated to helping innovators transform life-changing ideas and breakthrough science into new medical treatments. We offer strategic solutions across the entire development lifecycle, from pre-clinical through commercialization, specializing in smart study design and full-service clinical trial management.
Leveraging technology and therapeutic expertise, we deliver clean, conclusive data with a focus on reducing development timelines, securing access to the right patients, and effectively navigating global regulations to ensure submission-ready results.
As an organization that puts patients first, we pride ourselves on helping customers answer the unmet needs of patients across a broad range of medical conditions. Visit premier-research.com.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account